137 related articles for article (PubMed ID: 37806264)
61. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.
Hornberger J; Reyes C; Shewade A; Lerner S; Friedmann M; Han L; Gutierrez H; Satram-Hoang S; Keating MJ
Leuk Lymphoma; 2012 Feb; 53(2):225-34. PubMed ID: 21824050
[TBL] [Abstract][Full Text] [Related]
63. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.
Johnson PC; Woyach JA; Ulrich A; Marcotte V; Nipp RD; Lage DE; Nelson AM; Newcomb RA; Rice J; Lavoie MW; Ritchie CS; Bartlett N; Stephens DM; Ding W; Owen C; Stone R; Ruppert AS; Mandrekar SJ; Byrd JC; El-Jawahri A; Le-Rademacher J; Rosko A
J Geriatr Oncol; 2023 Jul; 14(6):101538. PubMed ID: 37329769
[TBL] [Abstract][Full Text] [Related]
64. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Blommestein HM; de Groot S; Aarts MJ; Vemer P; de Vries R; van Abeelen AF; Posthuma EF; Uyl-de Groot CA
Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
[TBL] [Abstract][Full Text] [Related]
66. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Bravaccini S; Martinelli G; Cerchione C
Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
[TBL] [Abstract][Full Text] [Related]
67. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
[TBL] [Abstract][Full Text] [Related]
68. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India.
Nehra P; Chauhan AS; Malhotra P; Kumar L; Singh A; Gupta N; Mehra N; Mathew A; Kataki AC; Gupta S; Prinja S
Lancet Reg Health Southeast Asia; 2023 Jun; 13():100201. PubMed ID: 37383548
[TBL] [Abstract][Full Text] [Related]
70. Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Irwin D; Wilson K; Thompson S; Choudhry A
Curr Med Res Opin; 2021 Apr; 37(4):623-628. PubMed ID: 33563073
[TBL] [Abstract][Full Text] [Related]
71. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
74. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Casado LF; Burgos A; González-Haba E; Loscertales J; Krivasi T; Orofino J; Rubio-Terres C; Rubio-Rodríguez D
Clinicoecon Outcomes Res; 2016; 8():475-484. PubMed ID: 27703384
[TBL] [Abstract][Full Text] [Related]
75. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Šimkovič M; Shadman M; Österborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trněný M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Lancet Oncol; 2022 Aug; 23(8):1031-1043. PubMed ID: 35810754
[TBL] [Abstract][Full Text] [Related]
76. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
[TBL] [Abstract][Full Text] [Related]
77. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
78. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V
Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437
[TBL] [Abstract][Full Text] [Related]
79. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
80. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]